Procter & Gamble Pharmaceuticals has launched Asacol HD (mesalamine) delayed-release tablets for the treatment of moderately active ulcerative colitis (UC), a form of inflammatory bowel disease. UC involves inflammation of the lining of the colon and rectum and is typically characterized by flares followed by periods of remission. Asacol HD 4.8 g/day 800 mg tablet was approved by the US FDA.